BREAST CANCER

Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses molecular targets in inflammatory breast cancer.

Palbociclib plus letrozole is tolerable and more than doubles progression-free survival (PFS) for postmenopausal patients with locally advanced or newly diagnosed estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, according to final results from the phase II PALOMA-1 trial

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.

Researchers have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including one for which targeted agents have been approved in other cancers.

Julie R. Gralow, MD, gives an overview of a phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer.

Sharon Tollin, PhD, ARNP-BC, OCN®, H. Lee Moffitt Cancer Center & Research Institute, discusses changes to the awareness of BRCA testing and breast cancer risk.

Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.

The I-SPY 2 trial, which is evaluating novel agents in the neoadjuvant treatment of breast cancer, may accelerate and influence the way that oncology drugs are tested and approved in the near future.

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the Myriad myRisk Hereditary Cancer Test.

The development of predictive biomarkers is widely accepted as an important milestone in the move toward personalized, or precision, medicine and the ability to identify the right drug for the right patient. JTT interviewed Kopetz about biomarker models.

Laura J. Esserman, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses the I-SPY 2 trial, a clinical trial for women with newly diagnosed, locally advanced breast cancer.

Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.

Edith A. Perez, MD, discusses the antibody drug conjugate T-DM1 (trastuzumab emtansine; Kadcyla) as a treatment for patients with breast cancer.

Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study looking at eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.

Matthew J. Ellis, MD, PhD, discusses the ongoing phase III FALCON trial.

Nicholas Turner, PhD, consultant medical oncologist, The Royal Marsden Hospital, London, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.

Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.

According to results of the Phase III SWOG S0500 clinical trial, switching chemotherapy based on level of elevated CTCs after one cycle of chemotherapy did not improve OS or PFS in women with metastatic breast cancer.

Study investigators reported at the 2013 San Antonio Breast Cancer Symposium that the addition of carboplatin to standard neoadjuvant chemotherapy increased pathologic complete response (pCR) rates in patients with triple-negative breast cancer (TNBC).

According to the results of a prospective, randomized, controlled trial, in women with metastatic breast cancer that responds to frontline chemotherapy, locoregional treatment (LRT) of the primary tumor and axillary nodes does not produce an increase in overall survival (OS).

Findings reported at the 2013 San Antonio Breast Cancer Symposium showed that PIK3CA-mutated tumors in patients with HER2-positive (HER+) breast cancer (BC) are associated with a much lower rate of pathological complete response (pCR).

A new study reported at the 2013 San Antonio Breast Cancer Symposium shows that a prescribed exercise program reduces joint pain in breast cancer survivors taking aromatase inhibitors (AIs), with pain reductions observed at all levels of exercise.

According to newly reported findings from the International Breast Cancer Intervention Study II (IBIS-II), anastrozole may be a new option for primary prevention of breast cancer in postmenopausal women at high risk for the disease.

In women with hormone receptor-positive, HER2-negative metastatic breast cancer, the addition of dasatinib to standard aromatase inhibitor therapy with letrozole doubled progression-free survival (PFS) compared with letrozole alone.

If treated with hormonal therapy and considered to be at low risk for breast cancer recurrence, women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy (RT) after breast conserving surgery.

Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.

Rodrigo Goncalves, MD, postdoctoral fellow, Washington University School of Medicine, discusses the development of a standardized Ki-67 assay.

According to results from the large randomized BETH trial, bevacizumab did not improve invasive disease-free survival (IDFS) or overall survival (OS) when added to adjuvant therapy for HER2-positive breast cancer.

Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.